Last edition
News about "taxane trastuzumab pertuzumab"
The European Union (EU) has approved Enhertu plus pertuzumab as a new first-line regimen for HER2-positive metastatic breast cancer, reducing progression or death risk by 44 percent.
Taxane Trastuzumab Pertuzumab | 02/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members